Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy

Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02527902

Enrollment

Registered

2015-08-19

Start date

2011-01-31

Completion date

2012-04-30

Last updated

2015-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IGA Glomerulonephritis

Keywords

IGA Glomerulonephritis, Autonomic nervous system, ANS

Brief summary

The estimation of the cardiovascular risk in the general population must take into account small renal disturbances, as the microalbuminuria. Conversely certain parameters of the cardiovascular risk influence the evolution of renal diseases, for example the arterial high blood pressure. The measure of the activity of the autonomous nervous system, and especially the quantification of its variability, is a means to estimate the cardiovascular risk. The investigators formulate the hypothesis that the variability of the autonomous nervous system is an additional clinical element for the evaluation of the evolutionary risk of renal diseases. The aim of this study is to compare the variability of the autonomous nervous system during the various evolutionary stages of the renal disease. The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the renal mesangium (at list 1+) by immunofluorescence.

Interventions

DEVICEHolter

measure of ANS in IgAN patients

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* diagnosis of IgNA biopsy-proven free, informed, express and written

Exclusion criteria

* IgNA secondary to Henoch-Schonlein purpura (HSP) or Systemic Lupus Erythematosus or alcoholic cirrhosis * current kidney transplantation * Hypertension treated or not, * Diseases interfering with ANS analysis: cardiac arrhythmia, beta-blocker therapy * diabetes

Design outcomes

Primary

Measure	Time frame	Description
Standard deviation of all R-R intervals (SDNN)	day 1	Comparison of Standard deviation of all R-R intervals (SDNN) between GFR category of IgNA

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026